Neoplastic growth is associated with increased
polyamine biosynthetic activity and content.
Tumor promoter treatment induces the rate-limiting
enzymes in
polyamine biosynthesis,
ornithine decarboxylase (ODC), and
S-adenosylmethionine decarboxylase (AdoMetDC), and targeted ODC overexpression is sufficient for
tumor promotion in initiated mouse skin. We generated a mouse model with
doxycycline (Dox)-regulated AdoMetDC expression to determine the impact of this second rate-limiting
enzyme on epithelial
carcinogenesis. TetO-AdoMetDC (TAMD) transgenic founders were crossed with transgenic mice (K5-tTA) that express the
tetracycline-regulated transcriptional activator within basal keratinocytes of the skin. Transgene expression in TAMD/K5-tTA mice was restricted to
keratin 5 (K5) target tissues and silenced upon Dox treatment. AdoMetDC activity and its product, decarboxylated
AdoMet, both increased approximately 8-fold in the skin. This enabled a redistribution of the
polyamines that led to reduced
putrescine, increased
spermine, and an elevated
spermine:
spermidine ratio. Given the positive association between
polyamine biosynthetic capacity and neoplastic growth, it was somewhat surprising to find that TAMD/K5-tTA mice developed significantly fewer
tumors than controls in response to 7,12-dimethylbenz[a]
anthracene/12-O-tetradecanoylphorbol-13-
acetate chemical
carcinogenesis. Importantly,
tumor counts in TAMD/K5-tTA mice rebounded to nearly equal the levels in the control group upon Dox-mediated transgene silencing at a late stage of
tumor promotion, which indicates that latent viable initiated cells remain in AdoMetDC-expressing skin. These results underscore the complexity of
polyamine modulation of
tumor development and emphasize the critical role of
putrescine in
tumor promotion. AdoMetDC-expressing mice will enable more refined spatial and temporal manipulation of
polyamine biosynthesis during
tumorigenesis and in other models of human disease.